| アブストラクト | BACKGROUND: Antidepressants are commonly prescribed for mood disorders. Epidemiological studies suggest antidepressant use may be associated with cataracts and glaucoma. We aim to investigate the association between antidepressants and cataracts and glaucoma. METHODS: Data was collected from the United States Food and Drug Administration Adverse Event Reporting System. Reporting odds ratio (ROR) and Bayesian information components (IC(025)) were calculated for antidepressants (ie, selective serotonin reuptake inhibitors [SSRIs], selective norepinephrine reuptake inhibitors [SNRIs], serotonin-norepinephrine-dopamine reuptake inhibitors, serotonin modulators and stimulators, serotonin antagonists and reuptake inhibitors [SARIs], norepinephrine reuptake inhibitors, norepinephrine-dopamine reuptake inhibitors, tricyclic antidepressants [TCAs], tetracyclic antidepressants [TeCAs], and monoamine oxidase inhibitors [MAOIs]). The reference agent was acetaminophen. RESULTS: TeCAs and MAOIs were significantly associated with a decreased risk of cataracts (ROR = 0.11-0.65 and 0.16-0.69, respectively). TCAs, brexanolone, esketamine, and opipramol reported an increased cataract risk (ROR = 1.31-12.81). For glaucoma, SSRIs, SNRIs, SARIs, TCAs, MAOIs, and other investigated antidepressants reported significant RORs ranging from 1.034 to 21.17. There was a nonsignificant association of angle closure glaucoma (ACG) and open angle glaucoma (OAG) with the investigated antidepressants. LIMITATIONS: For adverse event cases, multiple suspected product names are listed, and as cases are not routinely verified, there may be a possibility of duplicate reports and causality cannot be established. CONCLUSION: Most of the investigated antidepressants were associated with a lower risk of cataract reporting. TCAs, brexanolone, esketamine, and opipramol were associated with greater odds of cataract. For most antidepressants, there was an insignificant increase in reports of ACG and OAG. |
|---|
| 投稿者 | Le, Gia Han; Wong, Sabrina; Kwan, Angela T H; Rosenblat, Joshua D; Mansur, Rodrigo B; Teopiz, Kayla M; Ho, Roger; Rhee, Taeho Greg; Vinberg, Maj; Cao, Bing; Liao, Sonya; McIntyre, Roger S |
|---|
| 組織名 | Institute of Medical Science, University of Toronto, Toronto, ON, Canada.;Mood Disorder Psychopharmacology Unit, University Health Network, Toronto, ON,;Canada.;Brain and Cognition Discovery Foundation, Toronto, ON, Canada.;Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON,;Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.;Department of Psychiatry, University of Toronto, Toronto, ON, Canada.;Department of Psychological Medicine, Yong Loo Lin School of Medicine, National;University of Singapore, Singapore.;Institute for Health Innovation and Technology (iHealthtech), National University;of Singapore, Singapore.;Division of Life Science (LIFS), Hong Kong University of Science and Technology,;Hong Kong, China.;Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.;Department of Public Health Sciences, University of Connecticut School of;Medicine, Farmington, CT, USA.;Mental Health Centre Northern Zealand, The Early Multimodular Prevention and;Intervention Research Institution (EMPIRI) - Mental Health Services CPH,;Copenhagen, Denmark.;Department of Clinical Medicine, University of Copenhagen, CopenhagenDenmark.;Key Laboratory of Cognition and Personality, Faculty of Psychology, Ministry of;Education, Southwest University, Chongqing, P. R. China. |
|---|
